Drug Profile
Von Willebrand factor - LFB
Alternative Names: vWF SD-35-DH; Wilfactin; Willefact; WillfactLatest Information Update: 17 Oct 2021
Price :
$50
*
At a glance
- Originator LFB
- Developer AOP Orphan Pharmaceuticals AG; LFB
- Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant proteins
- Mechanism of Action Von willebrand factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Von Willebrand disease
Most Recent Events
- 17 Apr 2015 The product is approved in Estonia, Hungary, Latvia, Lithuania, Sweden, Slovakia and Slovenia for Von Willebrand's disease
- 11 Oct 2013 No development reported - Phase-II for Von Willebrand's disease in USA (Parenteral)
- 03 Apr 2013 Launched for Von Willebrand's disease in Norway (Parenteral)